WEBULL
WebtradeDownload

Harrow Stock What Changed After Revenue Growth And TYRVAYA Deal

Simply Wall St · 2d ago
  • Harrow reported third quarter 2026 revenue of US$99.3 million and net income of US$9.76 million, reaffirmed full year 2026 revenue guidance of US$350 million to US$365 million, and updated its adjusted EBITDA outlook, while also completing the TYRVAYA acquisition.
  • The launch of HarrowRx and the TYRVAYA acquisition move Harrow further toward a scaled, multi product ophthalmic platform that connects prescribing, access, and an expanded branded portfolio into a single commercial engine.
  • We will now look at how Harrow's record Q3 revenue and reaffirmed 2026 guidance reshape the broader investment narrative around execution.

Scan how Harrow’s latest quarter compares by lining up this earnings story against 20 high quality undiscovered gems with similar scale and fundamentals in adjacent sectors.

Harrow Investment Narrative Recap

To own Harrow, an investor needs to believe the branded ophthalmic platform can scale efficiently and that products like VEVYE, TRIESENCE, BYOOVIZ and TYRVAYA can support that build out. The record Q3 revenue of US$99.3 million and positive net income of US$9.76 million give that story more operational backing.

The short term catalyst remains execution against the reaffirmed 2026 revenue range of US$350 million to US$365 million after a lighter first half. The biggest risk is still concentration in a handful of brands, where any weaker prescription trends, reimbursement shifts, or pricing pressure could make that second half ramp harder to achieve.

The launch of HarrowRx looks tightly linked to these catalysts. By embedding Harrow’s portfolio in EMR workflows and routing prescriptions through a single point, the platform is designed to make it easier for practices to use and support branded products such as VEVYE and TYRVAYA across a larger patient base.

For shareholders watching the analyst consensus Narrative on Simply Wall St, HarrowRx sits right on the execution question. Better gross to net management and smoother access can help the business pursue its revenue guidance while trying to manage SG&A. The operational test is whether this infrastructure meaningfully supports prescription volumes across multiple franchises.

Harrow's narrative projects US$824.0 million of revenue and US$256.2 million of earnings by 2029, built on analysts' assumption of 44.1% yearly revenue growth and an earnings swing of roughly US$293.4 million from a loss of US$37.2 million today to the forecast consensus earnings figure.

Uncover why Harrow's fair value indicates a 108% potential upside to its current price. This suggests a discount that could close sooner than many expect.

NasdaqGM:HROW 1-Year Stock Price Chart
NasdaqGM:HROW 1-Year Stock Price Chart

Exploring Other Perspectives

For Harrow, the most optimistic analysts were already leaning hard into operating leverage before this earnings beat. They were pencilling in roughly US$946.8 million of revenue and US$306.2 million of earnings by 2029, far above consensus. You can read this quarter as a test of that bolder story, so it may be helpful to compare both views before deciding your own.

Explore 2 other Harrow fair value estimates, including one that suggests a potential upside of as much as 780% from the current price.

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own instincts.

  • A great starting point for your Harrow research is our analysis highlighting 3 key rewards that could impact your investment decision.
  • See our latest analysis for Harrow. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Harrow's overall financial health at a glance.

Looking for more Harrow sized investment ideas?

If Harrow has sharpened your thinking about scaled healthcare platforms, it can help to put that story beside other opportunities that share similar financial traits but sit in very different corners of the market.

The Simply Wall St Screener is built for exactly that kind of comparison, so you can pressure test your thesis across a broader set of businesses rather than focusing on a single stock.